TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* B-cell, CD20+ NHL~* Evidence of engraftment post-autologous peripheral blood stem cell transplant (PBSC-T), aka autologous stem cell transplant (ASCT)~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1~* Creatinine \< 2 mg/dL~* Bilirubin \< 2.0 mg/dL~* Liver function tests (LFTs) \< 5 x upper limit of normal (ULN)~Exclusion Criteria:~* Graft source from bone marrow~* Non-responders \[progressive disease (PD) or stable disease (SD)\] to prior anti-CD20 therapy~* PD after ASCT~* Post-ASCT radiotherapy~* Concomitant treatment with radiotherapy, chemotherapy or immunotherapy including rituximab~* Evidence of active pneumonitis~* Evidence of active infection~* Concurrent prednisone or other systemic steroid medication~* Nitrosourea therapy within 6 weeks of the first treatment with rituximab~* Presence of anti-murine antibody (HAMA) reactivity

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab after ASCT (Type: EXPERIMENTAL): Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Molecular diagnosis of DMD~* Patients 7 - 10 years of age at time of screening~* Ambulant~Exclusion Criteria:~* Previous (3 months or less) or concomitant participation in another therapeutic trial~* Use of L-arginine, L-citrulline or metformin within the last 3 months~* Known individual hypersensitivity to L-citrulline or metformin~* Other chronic disease or clinical relevant limitation of renal, liver, heart function according to discretion of the investigator

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- L-arginine and metformin (Type: EXPERIMENTAL): 7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quantitative Automated Lesion Detection of Traumatic Brain Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Control subjects from 18-50.~* Patients from 18-50 who have suffered TBI.~Exclusion Criteria:~* Substance abuse.~* Irremedial sensory deficits (blindness, deafness).~* Primary psychiatric disorder.~* Neurological disease unrelated to TBI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: no history of TBI (Type: None): 184 participants with no history of traumatic brain injury (TBI).
- Group 2: with a history of TBI (Type: None): 28 patients with a history of TBI. Most of these patients had suffered mild TBI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, \>40 years of age~2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior~3. Spontaneous amenorrhea for at least 12 consecutive months~4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause~5. Bilateral salpingo-oophorectomy \>6 weeks with or without hysterectomy~Exclusion Criteria:~1. History of hypersensitivity or adverse reaction to paroxetine mesylate~2. Use of an investigational study medication within 30 days prior to screening or during the study~3. Concurrent participation in another clinical trial or previous participation in this trial~4. Family of investigational-site staff

- Gender: FEMALE
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brisdelle (paroxetine mesylate) (Type: EXPERIMENTAL): Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
- Placebo - Sugar Pill (Type: PLACEBO_COMPARATOR): Eligible subjects will be randomized to receive a sugar pill.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/guardian (legally authorized representative) has given voluntary written consent to the subject's participation after being fully informed of the purpose, methods, risks, and benefits of the study.~* Male and female children who have completed the primary 3 doses of JEV in the KD287-BR-CT-301study.~* Male and female children reaching at least 6 years of age on the day of booster dosing of JEV.~* Male and female children who are identified to be healthy based on physical examination and medical history.~Exclusion Criteria:~* Children who have acute febrile illness with tympanic temperature of ≥38.0 ℃ on the day of booster dosing of JEV.~* Children who have moderate or severe acute disease (regardless of fever).~* Children who have history of encephalitis, encephalopathy, cerebromeningitis, or convulsion.~* Children who have received JEV (including live JEV) other than the investigational products administered in the KD287-BR-CT-301study.~* Children who have had fever (≥ 40 °C) or systemic allergy within 48 hours after vaccination.~* Children who have shown anaphylactic reaction to the investigational products administered in the KD287-BR-CT-301study or who are likely to be allergic to the ingredients of the investigational product.~* Children who have been diagnosed with immunodeficiency such as acquired immune deficiency or who have family history of immunodeficiency.~* Children who have received other vaccines within 28 days before booster dosing of JEV (vaccines to be administered according to the national vaccination program.~* Children who have received immunosuppressive thera-py within 28 days before booster dosing of JEV.~* There is a possibility that immune globulin preparations has not been excreted enough on the day of booster dosing of JEV if children have received such a product.~* Children who are currently participating or planning to participate in other clinical stud-ies during the study period.~* Other ineligible conditions judged at the discretion of principal investigators or subinvestigators.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- Japanese encephalitis vaccine (Type: OTHER): After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* planned elective cholecystectomy~Exclusion Criteria:~* small bowel resection~* right sided hemicolectomy~* known chronic diarrheal disease (celiac disease, lactose malabsorption, Inflammatory bowel diseases, incl microscopic colitis)~* pregnancy~* wish for pregnancy within next three months~* allergy to eggs~* allergy to constituents in Xenbilox (capsules with chenodeoxycholic acid)~* acute cholecystitis within two months~* chronic cholecystitis~* cirrhosis of the liver~* suspected obstructive choledocholithiasis~* icterus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): chenodeoxycholic acid 1250mg po.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Patients with HDM-associated allergic rhinitis (AR) for at least 1 year~* Patients sensitized to D. pteronyssinus (D. pte) and/or D. farinae (D. far) defined on skin prick test and HDM-specific serum IgE~Main Exclusion Criteria:~* A history of rhinitis, rhinoconjunctivitis or asthma to allergens other than HDM, likely to result in rhinitis symptoms during the evaluation periods~* Partly controlled or uncontrolled asthma~* Controlled asthma requiring controller treatment(s) consistent with GINA 2014 treatment Steps 3 to 5

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (Type: ACTIVE_COMPARATOR): 300 IR tablet of HDM Allergen Extracts
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Imatinib in Desmoid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological confirmed aggressive fibromatosis (desmoid tumor)~* Measurable disease according to the RECIST criteria~* Evidence of relapse or disease progression within the last 6 months (based on RECIST criteria) in computed tomography or magnetic resonance imaging~* No possibility of complete surgical resection or cases in which surgical therapy leaving a large tissue defect, functional deficit or disfigurement would be required~* No possibility of curative radiotherapy with acceptable toxicity and/or late morbidity~* Previous treatment of the tumor region by surgical intervention and/or radiotherapy and/or antihormonal therapy possible~* Age \> or = 18 years~* WHO PS \< or = 1~* Effective contraception during study medication~* Signed informed consent form~Exclusion Criteria:~* Surgical intervention \< 4 weeks~* Prior therapy with imatinib~* Pregnancy or lactation~* Severe hepatic dysfunction~* Known allergic reaction to imatinib or one of its components~* The following laboratory values: Absolute neutrophil count \< 1.5 x 103/mm3, Platelets \< 100,000/mm3, Serum creatinine \> or = 2.5 mg/dl, SGOT and/or SGPT \> 2.5 x ULN (upper limit of normal), Total bilirubin \> 1.5 x ULN~* Participation in another study (four weeks before and during the study)~* Prior malignancy apart from completely resected basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- drug (Type: EXPERIMENTAL): Imatinib 800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Severe alcohol use disorder~* High-risk alcohol consumption~Exclusion Criteria:~* Patient with orthostatic hypotension~* Patient with hypotension~* History of uncontrolled hypertension~* Patient at risk for urinary retention associated with urethroprostatic disorders~* Patient with a clinically-active malignancy~* Patient with a confirmed cirrhosis~* History of bronchial asthma~* History of uncontrolled hyperthyroidism~* History of cardiovascular disease not under control~* Severe psychiatric disorder~* History of alcohol withdrawal syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose group (Type: EXPERIMENTAL): Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
- High-dose group (Type: EXPERIMENTAL): Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg \[2 tablets of 5 mg\] once a day slow-release: evening administration)
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* met the ROME III criteria for FD;~* education level no lower than high school;~* Hospital Anxiety and Depression Scale (HADS) score \> 8 respectively;~* absence of abnormalities in physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), abdominal ultrasonography and upper GI endoscopy within 6 months;~* absence of H. pylori infection~Exclusion Criteria:~* known allergy to omeprazole, flupenthixol or melitracen;~* any evidence of organic digestive diseases;~* reflux-related symptoms only (e.g., retrosternal pain, burning and regurgitation) or predominantly reflux-related symptoms;~* severe psychological symptoms that affected life and work;~* pregnancy or breastfeeding;~* recent myocardial infarction or cardiac arrhythmias;~* previous gastric surgery;~* use of PPIs, psychoactive drugs or other drugs that might affect gastric function within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Flupentixol-Melitracen(psychological and GI) + Omeprazole (Type: ACTIVE_COMPARATOR): The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
- Flupentixol-Melitracen(psychological) + Omeprazole (Type: ACTIVE_COMPARATOR): The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
- Flupentixol-Melitracen(without explanation) + Omeprazole (Type: ACTIVE_COMPARATOR): In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
- proton pump inhibitor (Type: ACTIVE_COMPARATOR): Prescribe Omeprazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, aged 18 years or older~2. ARV multi-experienced patients (i.e. experienced at least two prior regimens) with need to change current ARV therapy, including:~   * HIV-1 infected patients with documented therapeutic failure,~  * HIV-2 infected patients with documented therapeutic failure~  * HIV infected patients in virologic suppression who needed to change ARV due to inacceptable toxicity, as determined by the investigator, including patients who needed to replace T20~3. Raltegravir-naïve patients who initiated raltegravir since the EAP Program, with optimized background therapy(OBT)~4. Patient who has been followed at the same clinical site since the start of raltegravir~Exclusion Criteria:~1. Acute or decompensated chronic hepatitis. Patients with serum aminotransferase levels 10 times the upper limit of the normal range or higher (grade 4)~2. Patients who presented resistance to drugs included in OBT (namely, etravirine, darunavir or maraviroc)~3. Non-existing medical records for viral load and TCD4 at baseline, week 24 and 48

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CohortHIV (Type: None): Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ECT Pulse Amplitude and Medial Temporal Lobe Engagement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of major depressive disorder (with or without psychotic features)~2. the clinical indications for ECT including treatment resistance or a need for a rapid and definitive response~3. Hamilton Depression Rating Scale 24-item (HDRS-24) \> 21~4. age range between 50 and 80 years of age~5. right-handedness~Exclusion Criteria:~1. Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness \> 5 minutes, epilepsy, Alzheimer's disease)~2. other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)~3. current drug or alcohol use disorder, except for nicotine; and 4) contraindications to MRI.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 600 mA Right Unilateral ECT (Type: EXPERIMENTAL): MECTA Spectrum 5000Q Amplitude
- 700 mA Right Unilateral ECT (Type: EXPERIMENTAL): MECTA Spectrum 5000Q Amplitude
- 800 mA Right Unilateral ECT (Type: ACTIVE_COMPARATOR): MECTA Spectrum 5000Q Amplitude

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: National Lung Screening Trial (NLST) Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 55-74 years (pack-years = packs per day \* years smoked)~* 30 or more pack-years of cigarette smoking history~* Former smokers: quit smoking within the previous 15 years~* Ability to lie on the back with arms raised over the head~* Signed informed consent form~Exclusion Criteria:~* Metallic implants or devices in the chest or back, such as pacemakers or Harrington fixation rods~* Treatment for, or evidence of, any cancer other than nonmelanoma skin cancer or carcinoma in situ (with the exception of transitional cell carcinoma in situ or bladder carcinoma in situ) in the 5 years prior to eligibility assessment~* History of lung cancer~* History of removal of any portion of the lung, excluding needle biopsy~* Requirement for home oxygen supplementation~* Participation in another cancer screening trial~* Participation in a cancer prevention study, other than a smoking cessation study~* Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility assessment~* Recent hemoptysis~* Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment~* Chest CT examination in the 18 months prior to eligibility assessment

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Low-Dose CT (Type: EXPERIMENTAL): None
- Chest X-ray (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete